Dermatology · Loveland, CO
NPI
1982044012
Since 2013
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
4025 St Cloud Dr Ste 110
Loveland, CO, 80538
Phone (970) 667-0304
Groups this clinician bills Medicare through
Medicare paid, 2024
$226K
4,844 services
Medicare patients, 2024
865
Average age 75
Drug cost, 2024
$2.1M
1,244 prescriptions
Company payments, 2025
$299K
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ammon Larsen was code 17003 (destruction skin lesion), 1,694 times for 347 patients. In total Ammon Larsen billed 4,844 services in 54 codes, and Medicare paid $226K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,694 | 347 | $5.09 | $8,625 |
| 17000 Destruction Skin Lesion | Office | 692 | 506 | $37.66 | $26K |
| 99213 Office E&M - Established | Office | 593 | 479 | $62.04 | $37K |
| 99214 Office E&M - Established | Office | 522 | 398 | $87.74 | $46K |
| 11102 Skin Biopsy | Office | 290 | 262 | $67.91 | $20K |
| 17110 Destruction Skin Lesion | Office | 282 | 243 | $80.46 | $23K |
| 11103 Skin Biopsy | Office | 104 | 66 | $40.11 | $4,172 |
| 99204 Office E&M - New | Office | 92 | 92 | $107.96 | $9,932 |
| 96372 Injection Administration | Office | 87 | 18 | $11.29 | $982 |
| 17262 Destruction Skin Lesion | Office | 67 | 53 | $114.13 | $7,646 |
| 99203 Office E&M - New | Office | 67 | 67 | $71.91 | $4,818 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 37 | 12 | $0.78 | $28.83 |
| 17004 Destruction Skin Lesion | Office | 25 | 22 | $130.72 | $3,268 |
| 17272 Destruction Skin Lesion | Office | 25 | 20 | $129.00 | $3,225 |
| 13121 Wound Repair - All Levels | Office | 24 | 24 | $329.87 | $7,917 |
By year: 2022 $236K for 4,978 services; 2023 $251K for 5,035 services; 2024 $226K for 4,844 services.
Medicare prescription drug claims, 2024
In 2024, the drug Ammon Larsen prescribed most often to Medicare patients was Clobetasol Propionate, with 214 prescriptions and refills. In total Ammon Larsen wrote 1,244 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 214 | 236 | 127 | $9,382 |
| Triamcinolone Acetonide Generic | 148 | 153 | 108 | $2,043 |
| Ketoconazole Generic | 108 | 114 | 63 | $3,131 |
| Dupixent Pen Dupilumab | 108 | 110 | 21 | $424K |
| Mupirocin Generic | 100 | 103 | 80 | $938 |
| Doxycycline Hyclate Generic | 52 | 54 | 32 | $959 |
| Rinvoq Upadacitinib | 39 | 41 | Under 11 | $256K |
| Clindamycin Phosphate Generic | 29 | 34 | 15 | $603 |
| Cosentyx Unoready Pen Secukinumab | 29 | 29 | Under 11 | $323K |
| Hydrocortisone Generic | 26 | 26 | 17 | $122 |
| Metronidazole Generic | 22 | 22 | 16 | $1,162 |
| Ivermectin Generic | 22 | 22 | Under 11 | $2,148 |
| Tacrolimus Generic | 19 | 20 | 19 | $3,941 |
| Odomzo Sonidegib Phosphate | 19 | 19 | Under 11 | $244K |
| Tretinoin Generic | 18 | 26 | Under 11 | $2,029 |
Brand drugs: 310 claims; generic drugs: 934 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ammon Larsen $299K ($299K in general payments such as food, travel and fees) from 18 companies. The largest payer was Galderma Laboratories, L.P. with $73K.
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. GALD.SW | 68 | $73K |
| Lilly USA, LLC LLY | 105 | $60K |
| UCB, Inc. UCB.BR | 96 | $56K |
| Abbvie Inc. ABBV | 41 | $45K |
| Genzyme Corporation SNY | 25 | $23K |
| Organon LLC OGN | 24 | $16K |
| LEO Pharma Inc. | 22 | $10K |
| Regeneron Healthcare Solutions, Inc. REGN | 21 | $7,650 |
| Pfizer Inc. PFE | 11 | $4,958 |
| Incyte Corporation INCY | 7 | $2,155 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.